ArticleCancer cell international2025
Targeting the MIR4435-2HG/miR-29c-3p/FSP1 axis overcomes lenvatinib resistance by inducing ferroptosis in hepatocellular carcinoma.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-Translational Modification Networks in Ferroptosis: Orchestrating Defense, Drug Resistance, and Therapeutic Opportunities in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLenvatinib resistance is a major clinical challenge in advanced hepatocellular carcinoma (HCC). While ferroptosis has emerged as a promising target to overcome therapy resistance, the mechanistic link between ferroptosis and lenvatinib resistance in HCC remains incompletely understood.
methodsWe analyzed clinical data from TCGA-LIHC and performed functional assays in two HCC cell lines. RNA antisense purification sequencing (RAP-seq) was used to identify downstream targets, and the mechanisms were validated by dual-luciferase reporter assays and Western blotting. Ferroptosis was assessed by measuring lipid reactive oxygen species (lipid ROS) and labile iron levels. Therapeutic efficacy was evaluated both in vitro and in vivo.
resultsMIR4435-2HG was upregulated in HCC and associated with poorer overall survival. It promoted malignant phenotypes and was further upregulated in lenvatinib-resistant cell lines. Mechanistically, MIR4435-2HG functioned as a competing endogenous RNA (ceRNA) by sponging miR-29c-3p, resulting in upregulation of FSP1. This axis suppressed ferroptosis, thereby conferring lenvatinib resistance. Knockdown of MIR4435-2HG or inhibition of FSP1 synergized with lenvatinib to induce ferroptosis and overcome resistance. The combination strategy significantly suppressed tumor growth in vivo without apparent systemic toxicity.
conclusionOur findings identify a previously uncharacterized MIR4435-2HG/miR-29c-3p/FSP1 axis that promotes lenvatinib resistance by inhibiting ferroptosis, highlighting that targeting this axis may provide a mechanistic basis and preclinical rationale for overcoming lenvatinib resistance in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.